FOLH1 and prostate cancer: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agents, labeled with either 68Ga or 18F, for prostate cancer (PCa) or somatostatin receptor (SSTR)-targeted probes for imaging neuroendocrine tumors (NETs) are already widely utilized and in a variety of clinical contexts [5–9].